Sunday, October 4, 2026
ExploreSearch
Via News
MarketCommodities

Palladium Futures Slides By 8% In The Last 21 Sessions

ViaNews Editorial Team

October 6, 2023

Palladium Futures Slides By 8% In The Last 21 Sessions

(VIANEWS) - Palladium (PA) has been up by 8.13% for the last 21 sessions. At 02:54 EST on Friday, 6 October, Palladium (PA) is $1,142.00.

Volume

Today's last reported volume for Palladium is 380, 99.99% below its average volume of 4122838214.81.

Volatility

Palladium's last week, last month's, and last quarter's current intraday variation average was a negative 1.90%, a positive 0.25%, and a positive 1.45%, respectively.

Palladium's highest amplitude of average volatility was 1.93% (last week), 1.51% (last month), and 1.45% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Palladium's commodity is considered to be overbought (>=80).

News about

  • According to FXStreet on Wednesday, 4 October, "West Texas Intermediary (WTI) Crude Oil trades lower around $88.00 per barrel by the press time."

More news about Palladium (PA).

Categories

MarketCommodities

Tags

CommodityCommoditiesFuturesPAPalladiumPrice DownCommodities Price DownCommodities Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com